The health authorities regulatory restriction of the prescription of anti-EGFR monoclonal antibodies to wild-type KRAS tumor patients plays a major role in selecting anti-VEGF or anti-EGFR introduction in first-line therapy. The gene discussed is EGFR; the disease is neoplasm.